Amendments to the Claims:

The following listing of claims will replace all prior versions and listings of claims.

Listing of Claims

1-19. (canceled)

20. (new) An isolated antibody or fragment thereof that specifically binds to a protein selected from the group consisting of:

(a) a protein whose amino acid sequence consists of amino acid residues 1 to 93 of SEQ ID NO:2;

(b) a protein whose amino acid sequence consists of amino acid residues 20 to 93 of SEQ ID NO:2;

(c) a protein whose amino acid sequence consists of a portion of SEQ ID NO:2, wherein said portion is at least 30 contiguous amino acid residues in length; and

(d) a protein whose amino acid sequence consists of a portion of SEQ ID NO:2, wherein said portion is at least 50 contiguous amino acid residues in length.

21. (new) The antibody or fragment thereof of claim 20 that specifically binds protein (a).

22. (new) The antibody or fragment thereof of claim 20 that specifically binds protein (b).

23. (new) The antibody or fragment thereof of claim 20 that specifically binds protein (c).

24. (new) The antibody or fragment thereof of claim 20 that specifically binds protein (d).

25. (new) The antibody or fragment thereof of claim 21 that specifically binds protein (b).

26. (new) The antibody or fragment thereof of claim 22 wherein said protein bound by said antibody or fragment thereof is glycosylated.

27. (new) The antibody or fragment thereof of claim 22 wherein said antibody or fragment thereof is human.

28. (new) The antibody or fragment thereof of claim 22 wherein said antibody or fragment thereof is polyclonal.

29. (new) The antibody or fragment thereof of claim 22 wherein said antibody or fragment thereof is monoclonal.

30. (new) The antibody or fragment thereof of claim 22 which is selected from the group consisting of:
(a) a chimeric antibody or fragment thereof;
(b) a humanized antibody or fragment thereof;
(c) a single chain antibody; and
(d) a Fab fragment.

31. (new) The antibody or fragment thereof of claim 22 which is labeled.

32. (new) The antibody or fragment thereof of claim 22 wherein said antibody or fragment thereof specifically binds to said protein in a Western blot or an ELISA.

33. (new) An isolated cell that produces the antibody or fragment thereof of claim 22.

34. (new) A hybridoma that produces the antibody or fragment thereof of claim 22.

35. (new) A method of detecting M-CIF protein in a biological sample comprising:
(a) contacting the biological sample with the antibody or fragment thereof of claim 22; and
(b) detecting the M-CIF protein in the biological sample.

36. (new) An isolated antibody or fragment thereof that specifically binds a M-CIF protein purified from a cell culture wherein said M-CIF protein is encoded by a polynucleotide encoding amino acids 1 to 93 of SEQ ID NO:2.

37. (new) The antibody or fragment thereof of claim 36 wherein said antibody or fragment thereof is monoclonal.

38. (new) The antibody or fragment thereof of claim 36 wherein said antibody or fragment thereof is polyclonal.

39. (new) The antibody or fragment thereof of claim 36 wherein said antibody or fragment thereof is human.

40. (new) The antibody or fragment thereof of claim 36 which is selected from the group consisting of:

(a) a chimeric antibody or fragment thereof;

(b) a humanized antibody or fragment thereof;

(c) a single chain antibody; and

(d) a Fab fragment.

41. (new) The antibody or fragment thereof of claim 36 wherein said antibody or fragment thereof specifically binds to said protein in a Western blot or an ELISA.

42. (new) The antibody or fragment thereof of claim 36 wherein the amino acid sequence of said M-CIF protein consists of amino acid residues 20 to 93 of SEQ ID NO:2.